Compared to CD45- myeloma cells, CD45+ myeloma cells with an activated JAK/STAT3 pathway are particularly sensitive to JAK2 inhibitor [54] which inhibits IL-6-induced JAK and STAT3 phosphorylation. Here, JAK2 is linked to plasma cell myeloma.